Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, Zuiverloon TCM (2025) Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification. Nat Rev Urol 22:75–91

Article  PubMed  Google Scholar 

Arthuso FZ, Fairey AS, Boulé NG, Courneya KS (2021) Bladder cancer and exeRcise trAining during intraVesical thErapy-the BRAVE trial: a study protocol for a prospective, single-centre, phase II randomised controlled trial. BMJ Open 11:e055782

Article  PubMed  PubMed Central  Google Scholar 

Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M (2022) Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol 19:280–294

Article  PubMed  Google Scholar 

Tang C, Liu H, Fan Y et al (2021) Functional nanomedicines for targeted therapy of bladder cancer. Front Pharmacol 12:778973

Article  PubMed  PubMed Central  CAS  Google Scholar 

Suh J, Yoo S (2020) Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer. Transl Cancer Res 9:6537–6545

Article  PubMed  PubMed Central  CAS  Google Scholar 

Uehara T, Watanabe S, Yamaguchi S et al (2023) Translocation of nuclear chromatin distribution to the periphery reflects dephosphorylated threonine-821/826 of the retinoblastoma protein (pRb) in T24 cells treated with Bacillus Calmette-Guérin. Cytotechnology 75:49–62

Article  PubMed  CAS  Google Scholar 

Low LS, Scholtz D, Leyland J, Nair SM (2021) A severe complication of intravesical bacillus Calmette-Guerin: an effect of different strains. Urol Case Rep 36:101592

PubMed  PubMed Central  Google Scholar 

Tsai T, Hwang TI, Chen P et al (2024) Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer. Int J Oncol. https://doi.org/10.3892/ijo.2024.5704

Article  PubMed  PubMed Central  Google Scholar 

Pijpers OM, Hendricksen K, Mostafid H et al (2022) Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol 40:62.e13-62.e20

Article  PubMed  CAS  Google Scholar 

Huang Z, Huang S, Wu E, He Q, Wei X, Liang W (2025) Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study. BMC Urol 25:81

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pazir Y, Esmeray A, Caglar U et al (2024) Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: A matched-pair analysis. Int Urol Nephrol 56:957–963

Article  PubMed  CAS  Google Scholar 

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339:b2700

Article  PubMed  PubMed Central  Google Scholar 

Guerrero-Ramos F, González-Padilla DA, González-Díaz A et al (2022) Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol 40:999–1004

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sachan A, Nayyar R, Pethe S, Singh P, Seth A (2024) A 3-arm randomized control trial to compare the efficacy of re-circulant hyperthermic intravesical chemotherapy versus conventional intravesical mitomycin C and BCG therapy for intermediate-risk non-muscle invasive bladder cancer. World J Urol 42:609

Article  PubMed  CAS  Google Scholar 

Tan WS, Panchal A, Buckley L et al (2019) Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy (HYMN): A phase III, open-label, randomised controlled trial. Eur Urol 75:63–71

Article  PubMed  Google Scholar 

Arends TJH, Nativ O, Maffezzini M et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk Non-Muscle-invasive bladder cancer. Eur Urol 69:1046–1052

Article  PubMed  CAS  Google Scholar 

Ekin RG, Akarken I, Zorlu F et al (2015) Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer. Can Urol Assoc J 9:E278–E283

Article  PubMed  PubMed Central  Google Scholar 

Elmasri M, Clark A, Grundy L (2024) Peripheral mechanisms underlying bacillus Calmette-Guerin-induced lower urinary tract symptoms (LUTS). Brain Sci. https://doi.org/10.3390/brainsci14121203

Article  PubMed  PubMed Central  Google Scholar 

Bourlotos G, Baigent W, Hong M, Plagakis S, Grundy L (2023) BCG induced lower urinary tract symptoms during treatment for NMIBC-mechanisms and management strategies. Front Neurosci 17:1327053

Article  PubMed  Google Scholar 

Thyavihally YB, Waigankar SS, Dev P et al (2021) Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette-Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer. Urol Ann 13:424–430

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zeng N, Xu M, Sun J et al (2023) Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis. Front Oncol 13:1164932

Article  PubMed  PubMed Central  CAS  Google Scholar 

Doisy L, Cimier A, Adypagavane A et al (2021) Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy. Int J Hyperthermia 38:1633–1638

Article  PubMed  CAS  Google Scholar 

Thomsen JA, Nielsen Dominiak H, Lindgren MS, Jensen JB (2021) Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients. Scand J Urol 55:281–286

Article  PubMed  CAS  Google Scholar 

Li X, Zheng J, Chen S, Meng F, Ning J, Sun S (2021) Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ATF4/CHOP pathway in breast cancer. Cell Death Dis 12:314

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ando K, Suzuki Y, Kaminuma T et al (2018) Tumor-specific CD8-positive T cell-mediated antitumor immunity is implicated in the antitumor effect of local hyperthermia. Int J Hyperthermia 35:226–231

Article  PubMed  Google Scholar 

Ruan Q, Ding D, Wang B et al (2021) A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer. Cancer Biol Med 18:308–317

Article  PubMed  PubMed Central  CAS  Google Scholar 

Serra-Burriel M, Aebersold H, Foster-Witassek F et al (2023) Real-world cost-effectiveness of pulmonary vein isolation for atrial fibrillation: a target trial approach. Value Health 26:1721–1729

Article  PubMed  Google Scholar 

Alsaati AA, Alsaadoun D, Kinkar LI, Alkhamis RS, Ahmed WA, Almathami AH (2023) The efficacy and safety of botulinum toxin A for the treatment of rosacea: a systematic review. Cureus 15:e51304

PubMed  PubMed Central  Google Scholar 

Berhane A, Belachew T (2022) Trend and burden of neural tube defects among cohort of pregnant women in Ethiopia: where are we in the prevention and what is the way forward? PLoS ONE 17:e0264005

Article  PubMed  PubMed Central  CAS  Google Scholar